1.646.889.1200|info@lifescipublicrelations.com

Reata buys drug rights back from AbbVie for $330M before readout

//Reata buys drug rights back from AbbVie for $330M before readout

Reata buys drug rights back from AbbVie for $330M before readout

Reata Pharmaceuticals said Thursday it will pay AbbVie $330 million over the next two years to re-acquire most of the ex-U.S. rights for its leading drug candidates.

By | 2019-10-21T12:42:03-04:00 October 10th, 2019|News|Comments Off on Reata buys drug rights back from AbbVie for $330M before readout

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.